×
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
NASDAQ:REPL

Replimune Group Stock Forecast, Price & News

$17.48
+0.03 (+0.17%)
(As of 06/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.67
$17.67
50-Day Range
$13.32
$18.63
52-Week Range
$13.05
$40.22
Volume
121,715 shs
Average Volume
351,390 shs
Market Capitalization
$857.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.57
30 days | 90 days | 365 days | Advanced Chart

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock Forecast (MarketRank)

Overall MarketRank

2.48 out of 5 stars

Medical Sector

150th out of 1,433 stocks

Biological Products, Except Diagnostic Industry

26th out of 217 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -
Replimune Group logo

About Replimune Group (NASDAQ:REPL)

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REPL Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
152
Year Founded
N/A

Company Calendar

Last Earnings
5/19/2022
Today
7/01/2022
Next Earnings (Estimated)
8/05/2022
Fiscal Year End
3/31/2023

Price Target and Rating

Average Stock Price Forecast
$47.57
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+172.1%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
7 Analysts

Profitability

Net Income
$-118.04 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.71 per share

Miscellaneous

Free Float
29,295,000
Market Cap
$857.74 million
Optionable
Not Optionable
Beta
2.30














Replimune Group Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Replimune Group stock.
View analyst ratings for Replimune Group
or view top-rated stocks.

What is Replimune Group's stock price forecast for 2022?

7 equities research analysts have issued 12-month target prices for Replimune Group's stock. Their REPL stock forecasts range from $30.00 to $60.00. On average, they predict Replimune Group's share price to reach $47.57 in the next twelve months. This suggests a possible upside of 172.1% from the stock's current price.
View analysts' price targets for Replimune Group
or view top-rated stocks among Wall Street analysts.

How has Replimune Group's stock price performed in 2022?

Replimune Group's stock was trading at $27.10 at the beginning of the year. Since then, REPL stock has decreased by 35.5% and is now trading at $17.48.
View the best growth stocks for 2022 here
.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for Replimune Group
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) posted its quarterly earnings data on Thursday, May, 19th. The company reported ($0.60) earnings per share for the quarter, meeting the consensus estimate of ($0.60).
View Replimune Group's earnings history
.

Who are Replimune Group's key executives?

Replimune Group's management team includes the following people:
  • Mr. Philip Astley-Sparke FSA, CEO & Director (Age 51, Pay $759.52k)
  • Dr. Robert Coffin Ph.D., Founder, Pres, Chief R&D Officer and Director (Age 57, Pay $759.52k)
  • Ms. Tanya N. Lewis M.S., Chief Devel. Operations Officer (Age 51, Pay $16.23k)
  • Ms. Jean M. Franchi, Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer (Age 56)
  • Dr. Colin A. Love Ph.D., Chief Operating Officer (Age 64)
  • Dr. Pamela Esposito Ph.D., Chief Bus. Officer (Age 47)
  • Mr. Sushil Patel Ph.D., Chief Commercial Officer (Age 51)

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

How do I buy shares of Replimune Group?

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $17.48.

How much money does Replimune Group make?

Replimune Group (NASDAQ:REPL) has a market capitalization of $857.74 million. The company earns $-118.04 million in net income (profit) each year or ($2.26) on an earnings per share basis.

How many employees does Replimune Group have?

Replimune Group employs 152 workers across the globe.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for Replimune Group is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at [email protected].

This page (NASDAQ:REPL) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.